Skip to main content
. 2023 Feb 24;13:3249. doi: 10.1038/s41598-023-30146-5

Figure 5.

Figure 5

Intended injection intervals at weeks 52 and 96 in 43 eyes with neovascular age-related macular degeneration associated with type 1 macular neovascularization treated with 3 monthly intravitreal injections of brolucizumab followed by a treat-and-extend regimen with intravitreal brolucizumab.